Search

Your search keyword '"Keymeulen, Bart"' showing total 557 results

Search Constraints

Start Over You searched for: Author "Keymeulen, Bart" Remove constraint Author: "Keymeulen, Bart"
557 results on '"Keymeulen, Bart"'

Search Results

2. Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium

3. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

10. Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes

12. Contributors

13. Vascularization of beta cell mass in device-encapsulated hPSC-derived pancreatic endoderm implants in subcutis of nude rats

17. Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

18. CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients

19. Comparison of Omentum and Subcutis as Implant Sites for Device-Encapsulated Human iPSC-Derived Pancreatic Endoderm in Nude Rats

21. Additional file 2 of First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

22. Additional file 1 of First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

23. CTLA4, SH2B3 and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of type 1 diabetes patients

24. OR03-6 Further Clinical Evaluation of Stem Cell-Derived Islet Replacement Therapy (VC-02) Demonstrates Production of C-Peptide with Improvements in Glycemic Control Parameters in Multiple Patients with Type 1 Diabetes and Hypoglycemia Unawareness

25. Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial

26. Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop

27. The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial

28. Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

29. Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus

32. 646-P: Sustained Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring in Adults with Type 1Diabetes: 24-Month Results of the ALERTT1 Trial

33. A Worldwide Survey of Activities and Practices in Clinical Islet of Langerhans Transplantation

44. Stem Cell-Derived Islet Replacement Therapy (VC-02) Demonstrates Production of C-Peptide in Patients with Type 1 Diabetes (T1D) and Hypoglycemia Unawareness

46. Lipohypertrophy Monitoring Study (LIMO): Effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: Confirmation of an unpleasant truth

47. Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus

48. The MicroRNA Landscape of Acute Beta Cell Destruction in Type 1 Diabetic Recipients of Intraportal Islet Grafts

49. Genetic variation at ERBB₃/IKZF₄ and sexual dimorphism in epitope spreading in single autoantibody-positive relatives

Catalog

Books, media, physical & digital resources